Skip to main content

Advertisement

SpringerLink
Log in

Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child

  • Reproductive Psychiatry and Women's Health (L Hantsoo and S Nagle-Yang, Section Editors)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To provide an updated summary and appraisal of work from 2019 to 2022 examining risks of selective serotonin reuptake inhibitor (SSRI) use in pregnancy.

Recent Findings

Perinatal SSRI exposure does not increase risk of major malformations or gestational diabetes after accounting for underlying maternal illness. SSRIs are associated with small increase in risk of pre-eclampsia, postpartum hemorrhage, preterm delivery, persistent pulmonary hypertension of the newborn, and neonatal intensive care unit admissions, though absolute risk of these outcomes is low. While data suggests no increased risk of neurodevelopmental disorders in offspring, mixed evidence indicates increased risk of adverse cognitive outcomes and affective disorders.

Summary

Recent evidence suggest low absolute risk of clinically relevant negative outcomes with perinatal SSRI exposure when compared to untreated perinatal depression. However, study design and ability to control for confounding remains an ongoing research challenge, highlighting need for ongoing rigorous study design and analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5 Pt 1):1071–83. https://doi.org/10.1097/01.AOG.0000183597.31630.db.

    Article  PubMed  Google Scholar 

  2. Force UPST. Interventions to prevent perinatal depression: US Preventive Services Task Force recommendation statement. JAMA. 2019;321(6):580–7. https://doi.org/10.1001/jama.2019.0007.

    Article  Google Scholar 

  3. Molenaar NM, Bais B, Lambregtse-van den Berg MP, Mulder CL, Howell EA, Fox NS, et al. The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability. J Affect Disord. 2020;264:82–9. https://doi.org/10.1016/j.jad.2019.12.014.

  4. Andrade SE, Reichman ME, Mott K, Pitts M, Kieswetter C, Dinatale M, et al. Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration’s Mini-Sentinel program. Arch Women’s Ment Health. 2016;19(6):969–77. https://doi.org/10.1007/s00737-016-0637-1.

  5. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194.e1-5. https://doi.org/10.1016/j.ajog.2007.07.036.

    Article  CAS  Google Scholar 

  6. Ornoy A, Koren G. SSRIs and SNRIs (SRI) in pregnancy: effects on the course of pregnancy and the offspring: how far are we from having all the answers? Int J Mol Sci. 2019;20(10). https://doi.org/10.3390/ijms20102370.

  7. Einarson A. The importance of critical evaluation of the literature regarding safety of antidepressant use in pregnancy. Acta Psychiatr Scand. 2013;127(2):115–6. https://doi.org/10.1111/acps.12046.

    Article  CAS  PubMed  Google Scholar 

  8. Swanson SA, Hernandez-Diaz S, Palmsten K, Mogun H, Olfson M, Huybrechts KF. Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. Pharmacoepidemiol Drug Saf. 2015;24(9):934–42. https://doi.org/10.1002/pds.3798.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Bérard A, Iessa N, Chaabane S, Muanda FT, Boukhris T, Zhao JP. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81(4):589–604. https://doi.org/10.1111/bcp.12849.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80(1):18–27. https://doi.org/10.1002/bdrb.20099.

    Article  CAS  PubMed  Google Scholar 

  11. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O’Brien L, Malm H, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 2007;29(5):918–26. https://doi.org/10.1016/j.clinthera.2007.05.003.

    Article  CAS  PubMed  Google Scholar 

  12. Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397–407. https://doi.org/10.1056/NEJMoa1312828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wang S, Yang L, Wang L, Gao L, Xu B, Xiong Y. Selective serotonin reuptake inhibitors (SSRIs) and the risk of congenital heart defects: a meta-analysis of prospective cohort studies. J Am Heart Assoc. 2015;4(5). https://doi.org/10.1161/jaha.114.001681.

  14. •• Anderson KN, Lind JN, Simeone RM, Bobo WV, Mitchell AA, Riehle-Colarusso T, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. JAMA Psychiat. 2020;77(12):1246–55. https://doi.org/10.1001/jamapsychiatry.2020.2453. This large case-control study demonstrates that associations between individual SSRIs and congenital heart defects disappear after adjusting for confounding by indication.

    Article  Google Scholar 

  15. Wisner KL, Oberlander TF, Huybrechts KF. The association between antidepressant exposure and birth defects—are we there yet? JAMA Psychiat. 2020;77(12):1215–6. https://doi.org/10.1001/jamapsychiatry.2020.1512.

    Article  Google Scholar 

  16. De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E. A systematic review and meta-analysis considering the risk for congenital heart defects of antidepressant classes and individual antidepressants. Drug Saf. 2021;44(3):291–312. https://doi.org/10.1007/s40264-020-01027-x.

    Article  CAS  PubMed  Google Scholar 

  17. Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. J Psychiatr Res. 2020;124:99–108. https://doi.org/10.1016/j.jpsychires.2020.02.023.

    Article  PubMed  Google Scholar 

  18. Melov SJ, Shetty PS, Pasupathy D, Kirby A, Sholler GF, Winlaw DS, et al. Selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitors and epidemiological characteristics associated with prenatal diagnosis of congenital heart disease. Prenat Diagn. 2021;41(1):35–42. https://doi.org/10.1002/pd.5846.

    Article  CAS  PubMed  Google Scholar 

  19. Gadot Y, Koren G. The use of antidepressants in pregnancy: focus on maternal risks. J Obstet Gynaecol Can. 2015;37(1):56–63. https://doi.org/10.1016/s1701-2163(15)30364-9.

    Article  PubMed  Google Scholar 

  20. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernández-Díaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry. 2009;166(3):320–8. https://doi.org/10.1176/appi.ajp.2008.08060817.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40(10):1723–33. https://doi.org/10.1017/s0033291709992194.

    Article  CAS  PubMed  Google Scholar 

  22. Palmsten K, Hernández-Díaz S, Huybrechts KF, Williams PL, Michels KB, Achtyes ED, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ. 2013;347: f4877. https://doi.org/10.1136/bmj.f4877.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Jiang HY, Xu LL, Li YC, Deng M, Peng CT, Ruan B. Antidepressant use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis. J Psychiatr Res. 2016;83:160–7. https://doi.org/10.1016/j.jpsychires.2016.09.001.

    Article  PubMed  Google Scholar 

  24. Lupattelli A, Spigset O, Koren G, Nordeng H. Risk of vaginal bleeding and postpartum hemorrhage after use of antidepressants in pregnancy: a study from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol. 2014;34(1):143–8. https://doi.org/10.1097/jcp.0000000000000036.

    Article  CAS  PubMed  Google Scholar 

  25. Palmsten K, Huybrechts KF, Michels KB, Williams PL, Mogun H, Setoguchi S, et al. Antidepressant use and risk for preeclampsia. Epidemiology. 2013;24(5):682–91. https://doi.org/10.1097/EDE.0b013e31829e0aaa.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Qiu C, Sanchez SE, Lam N, Garcia P, Williams MA. Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study. BMC Womens Health. 2007;7:15. https://doi.org/10.1186/1472-6874-7-15.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol. 2000;95(4):487–90. https://doi.org/10.1016/s0029-7844(99)00602-x.

    Article  CAS  PubMed  Google Scholar 

  28. Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32. https://doi.org/10.1016/j.phrs.2016.08.017.

    Article  CAS  PubMed  Google Scholar 

  29. Paton C, Ferrier IN. SSRIs and gastrointestinal bleeding. BMJ. 2005;331(7516):529–30. https://doi.org/10.1136/bmj.331.7516.529.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Skalkidou A, Sundström-Poromaa I, Wikman A, Hesselman S, Wikström AK, Elenis E. SSRI use during pregnancy and risk for postpartum haemorrhage: a national register-based cohort study in Sweden. BJOG. 2020;127(11):1366–73. https://doi.org/10.1111/1471-0528.16210.

    Article  CAS  PubMed  Google Scholar 

  31. •• Palmsten K, Chambers CD, Wells A, Bandoli G. Patterns of prenatal antidepressant exposure and risk of preeclampsia and postpartum haemorrhage. Paediatr Perinat Epidemiol. 2020;34(5):597–606. https://doi.org/10.1111/ppe.12660. This health claims data study describes a dose-dependent increase in risk of pre-eclampsia and postpartum hemorrhage with perinatal SSRI exposure.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kim DR, Pinheiro E, Luther JF, Eng HF, Dills JL, Wisniewski SR, et al. Is third trimester serotonin reuptake inhibitor use associated with postpartum hemorrhage? J Psychiatr Res. 2016;73:79–85. https://doi.org/10.1016/j.jpsychires.2015.11.005.

    Article  PubMed  Google Scholar 

  33. Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. Ann Pharmacother. 2018;53(2):186–94. https://doi.org/10.1177/1060028018794005.

    Article  CAS  PubMed  Google Scholar 

  34. Heller HM, Ravelli ACJ, Bruning AHL, de Groot CJM, Scheele F, van Pampus MG, et al. Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. BMC Pregnancy Childbirth. 2017;17(1):166. https://doi.org/10.1186/s12884-017-1334-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bolte AC, van Geijn HP, Dekker GA. Pathophysiology of preeclampsia and the role of serotonin. Eur J Obstet Gynecol Reprod Biol. 2001;95(1):12–21. https://doi.org/10.1016/s0301-2115(00)00367-5.

    Article  CAS  PubMed  Google Scholar 

  36. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum. 1999;42(12):2561–8. https://doi.org/10.1002/1529-0131(199912)42:12%3c2561::Aid-anr8%3e3.0.Co;2-u.

    Article  CAS  PubMed  Google Scholar 

  37. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull. 1996;32(4):653–8.

    CAS  PubMed  Google Scholar 

  38. Salvi V, Grua I, Cerveri G, Mencacci C, Barone-Adesi F. The risk of new-onset diabetes in antidepressant users - a systematic review and meta-analysis. PLoS ONE. 2017;12(7): e0182088. https://doi.org/10.1371/journal.pone.0182088.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194(4):961–6. https://doi.org/10.1016/j.ajog.2006.02.019.

    Article  CAS  PubMed  Google Scholar 

  40. Dandjinou M, Sheehy O, Bérard A. Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case-control study. BMJ Open. 2019;9(9): e025908. https://doi.org/10.1136/bmjopen-2018-025908.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Wartko PD, Weiss NS, Enquobahrie DA, Chan KCG, Stephenson-Famy A, Mueller BA, et al. Antidepressant continuation in pregnancy and risk of gestational diabetes. Pharmacoepidemiol Drug Saf. 2019;28(9):1194–203. https://doi.org/10.1002/pds.4799.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. • Lupattelli A, Barone-Adesi F, Nordeng H. Association between antidepressant use in pregnancy and gestational diabetes mellitus: results from the Norwegian Mother, Father and Child Cohort Study. Pharmacoepidemiol Drug Saf. 2022;31(2):247–56. https://doi.org/10.1002/pds.5388. This study indicates that perinatal exposure to antidepressants with low H1-receptor affinity, which includes all SSRIs, does not increase risk of gestational diabetes.

    Article  CAS  PubMed  Google Scholar 

  43. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A. 2011;91(3):142–52. https://doi.org/10.1002/bdra.20773.

    Article  CAS  Google Scholar 

  44. El Marroun H, Jaddoe VWV, Hudziak JJ, Roza SJ, Steegers EAP, Hofman A, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry. 2012;69(7):706–14. https://doi.org/10.1001/archgenpsychiatry.2011.2333.

    Article  PubMed  Google Scholar 

  45. Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014;36(1):13–8. https://doi.org/10.1016/j.genhosppsych.2013.08.002.

    Article  PubMed  Google Scholar 

  46. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors literature review and implications for clinical applications. JAMA. 2005;293(19):2372–83. https://doi.org/10.1001/jama.293.19.2372.

    Article  CAS  PubMed  Google Scholar 

  47. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87. https://doi.org/10.1056/NEJMoa052744.

    Article  CAS  PubMed  Google Scholar 

  48. Ross LE, Grigoriadis S, Mamisashvili L, VonderPorten EH, Roerecke M, Rehm J, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiat. 2013;70(4):436–43. https://doi.org/10.1001/jamapsychiatry.2013.684.

    Article  Google Scholar 

  49. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142–51. https://doi.org/10.1001/jama.2015.5605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Fitton CA, Steiner MFC, Aucott L, Pell JP, Mackay DF, Fleming M, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. Acta Psychiatr Scand. 2020;141(1):21–33. https://doi.org/10.1111/acps.13120.

    Article  CAS  PubMed  Google Scholar 

  51. Wolgast E, Lilliecreutz C, Sydsjö G, Bladh M, Josefsson A. The impact of major depressive disorder and antidepressant medication before and during pregnancy on obstetric and neonatal outcomes: a nationwide population-based study. Eur J Obstet Gynecol Reprod Biol. 2021;257:42–50. https://doi.org/10.1016/j.ejogrb.2020.11.062.

    Article  CAS  PubMed  Google Scholar 

  52. Vlenterie R, van Gelder M, Anderson HR, Andersson L, Broekman BFP, Dubnov-Raz G, et al. Associations between maternal depression, antidepressant use during pregnancy, and adverse pregnancy outcomes: an individual participant data meta-analysis. Obstet Gynecol. 2021;138(4):633–46. https://doi.org/10.1097/aog.0000000000004538.

    Article  PubMed  Google Scholar 

  53. Kieler H, Artama M, Engeland A, Ericsson Ö, Furu K, Gissler M, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012;344: d8012. https://doi.org/10.1136/bmj.d8012.

    Article  CAS  PubMed  Google Scholar 

  54. • Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. Am J Obstet Gynecol. 2019;220(1):57.e1-.e13. https://doi.org/10.1016/j.ajog.2018.08.030. This network meta-analysis demonstrates that perinatal SSRI exposure is associated with low absolute risk of persistent pulmonary hypertension of the newborn, with sertraline having lowest risk compared to other antidepressants.

  55. Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an update meta-analysis. J Womens Health (Larchmt). 2019;28(3):331–8. https://doi.org/10.1089/jwh.2018.7319.

    Article  Google Scholar 

  56. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4(12):1002–12. https://doi.org/10.1038/nrn1256.

    Article  CAS  PubMed  Google Scholar 

  57. Sujan AC, Öberg AS, Quinn PD, D’Onofrio BM. Annual research review: maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research. J Child Psychol Psychiatry. 2019;60(4):356–76. https://doi.org/10.1111/jcpp.13004.

    Article  PubMed  Google Scholar 

  58. Grzeskowiak LE, Morrison JL, Henriksen TB, Bech BH, Obel C, Olsen J, et al. Prenatal antidepressant exposure and child behavioural outcomes at 7 years of age: a study within the Danish National Birth Cohort. BJOG. 2016;123(12):1919–28. https://doi.org/10.1111/1471-0528.13611.

    Article  CAS  PubMed  Google Scholar 

  59. Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics. 2014;133(5):e1241–8. https://doi.org/10.1542/peds.2013-3406.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Santucci AK, Singer LT, Wisniewski SR, Luther JF, Eng HF, Dills JL, et al. Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes. J Clin Psychiatry. 2014;75(10):1088–95. https://doi.org/10.4088/JCP.13m08902.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Stein A, Pearson RM, Goodman SH, Rapa E, Rahman A, McCallum M, et al. Effects of perinatal mental disorders on the fetus and child. The Lancet. 2014;384(9956):1800–19. https://doi.org/10.1016/S0140-6736(14)61277-0.

    Article  Google Scholar 

  62. •• Dragioti E, Solmi M, Favaro A, Fusar-Poli P, Dazzan P, Thompson T, et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiat. 2019;76(12):1241–55. https://doi.org/10.1001/jamapsychiatry.2019.2859. This umbrella review of 45 meta-analyses suggests that the association between perinatal SSRI use and autism spectrum disorder studies attenuates after adjustment for confounding by indication.

    Article  Google Scholar 

  63. • Ames JL, Ladd-Acosta C, Fallin MD, Qian Y, Schieve LA, DiGuiseppi C, et al. Maternal psychiatric conditions, treatment with selective serotonin reuptake inhibitors, and neurodevelopmental disorders. Biol Psychiatry. 2021;90(4):253–62. https://doi.org/10.1016/j.biopsych.2021.04.002. This case-control study indicates that maternal psychiatric illness and not SSRI exposure significantly increases risk of neurodevelopmental disorders in offspring.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. • Rommel AS, Bergink V, Liu X, Munk-Olsen T, Molenaar NM. Long-term effects of intrauterine exposure to antidepressants on physical, neurodevelopmental, and psychiatric outcomes: a systematic review. J Clin Psychiatry. 2020;81(3). https://doi.org/10.4088/JCP.19r12965. A systematic meta-analysis of 34 studies shows no impact of antidepressant exposure on neurodevelopmental outcomes including cognition, behavior, IQ, motor development, speech, language, and scholastic outcomes, though does suggest increased risk of affective disorders in offspring.

  65. Lupattelli A, Mahic M, Handal M, Ystrom E, Reichborn-Kjennerud T, Nordeng H. Attention-deficit/hyperactivity disorder in children following prenatal exposure to antidepressants: results from the Norwegian mother, father and child cohort study. BJOG. 2021;128(12):1917–27. https://doi.org/10.1111/1471-0528.16743.

    Article  CAS  PubMed  Google Scholar 

  66. • Singal D, Chateau D, Struck S, Lee JB, Dahl M, Derksen S, et al. In utero antidepressants and neurodevelopmental outcomes in kindergarteners. Pediatrics. 2020;145(5). https://doi.org/10.1542/peds.2019-1157. This retrospective cohort study examines neurodevelopmental outcomes in school-aged children perinatal SSRI/SNRI exposure and suggests increased risk of developmental vulnerability in antidepressant-exposed children.

  67. • Christensen J, Trabjerg BB, Sun Y, Dreier JW. Association of maternal antidepressant prescription during pregnancy with standardized test scores of Danish school-aged children. JAMA. 2021;326(17):1725–35. https://doi.org/10.1001/jama.2021.17380. This retrospective cohort study examines cognitive outcomes in children exposed to SSRIs in utero. Exposed children had a statistically significant lower score by 2 points in mathematics compared to unexposed children, though the clinical relevance of this is thought to be small. There was no difference between the groups’ language scores.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Clements CC, Castro VM, Blumenthal SR, Rosenfield HR, Murphy SN, Fava M, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry. 2015;20(6):727–34. https://doi.org/10.1038/mp.2014.90.

    Article  CAS  PubMed  Google Scholar 

  69. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013;369(25):2406–15. https://doi.org/10.1056/NEJMoa1301449.

    Article  CAS  PubMed  Google Scholar 

  70. Malm H, Brown AS, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague IW, et al. Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: a national register-based study. J Am Acad Child Adolesc Psychiatry. 2016;55(5):359–66. https://doi.org/10.1016/j.jaac.2016.02.013.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children. JAMA. 2017;317(15):1544–52. https://doi.org/10.1001/jama.2017.3415.

    Article  CAS  PubMed  Google Scholar 

  72. Sujan AC, Rickert ME, Oberg AS, Quinn PD, Hernandez-Diaz S, Almqvist C, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA. 2017;317(15):1553–62. https://doi.org/10.1001/jama.2017.3413.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Dean K, Stevens H, Mortensen PB, Murray RM, Walsh E, Pedersen CB. Full spectrum of psychiatric outcomes among offspring with parental history of mental disorder. Arch Gen Psychiatry. 2010;67(8):822–9. https://doi.org/10.1001/archgenpsychiatry.2010.86.

    Article  PubMed  Google Scholar 

  74. Kingston D, Tough S, Whitfield H. Prenatal and postpartum maternal psychological distress and infant development: a systematic review. Child Psychiatry Hum Dev. 2012;43(5):683–714. https://doi.org/10.1007/s10578-012-0291-4.

    Article  PubMed  Google Scholar 

  75. Oyetunji A, Chandra P. Postpartum stress and infant outcome: a review of current literature. Psychiatry Res. 2020;284: 112769. https://doi.org/10.1016/j.psychres.2020.112769.

    Article  PubMed  Google Scholar 

  76. Slomian J, Honvo G, Emonts P, Reginster JY, Bruyère O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Womens Health (Lond). 2019;15:1745506519844044. https://doi.org/10.1177/1745506519844044.

    Article  CAS  Google Scholar 

  77. Grigoriadis S, Peer M. Antidepressants in pregnancy. In: Uguz F, Orsolini L, editors. Perinatal psychopharmacology. Cham: Springer International Publishing; 2019;69–98.

    Chapter  Google Scholar 

  78. Hunter LA, Catapano LA, Nagle-Yang SM, Williams KE, Osborne LM. Textbook of women’s reproductive mental health. Textbook of reproductive psychiatry. Am Psychiatr Pub. 2021.

Download references

Funding

This review was supported by funding from the Ludeman Family Center for Women’s Health Research at the University of Colorado (AMN) as well as NIH grant U54 AG062319 (AMN; PI Kohrt).

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Colorado School of Medicine, Anschutz Medical Campus, 1890 N Revere Court, Suite 5003, Aurora, CO, 80045, USA

    Lindsay G. Lebin & Andrew M. Novick

Authors
  1. Lindsay G. Lebin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew M. Novick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lindsay G. Lebin.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Reproductive Psychiatry and Women’s Health

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lebin, L.G., Novick, A.M. Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child. Curr Psychiatry Rep 24, 687–695 (2022). https://doi.org/10.1007/s11920-022-01372-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-022-01372-x

Keywords

Search

Navigation